<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01735838</url>
  </required_header>
  <id_info>
    <org_study_id>NL39385.060.12</org_study_id>
    <nct_id>NCT01735838</nct_id>
  </id_info>
  <brief_title>Intrathoracic Bloodvolume Measurement by Contrast Enhanced Ultrasound: Validation of the Technique and Evaluation as a Measurement of Response to Cardiac Resynchronization Therapy: a Pilot Study</brief_title>
  <official_title>Intrathoracic Bloodvolume Measurement by Contrast Enhanced Ultrasound: Validation of the Technique and Evaluation as a Measurement of Response to Cardiac Resynchronization Therapy: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catharina Ziekenhuis Eindhoven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catharina Ziekenhuis Eindhoven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Summary Rationale: Cardiac resynchronisation therapy (CRT) with biventricular pacemakers and&#xD;
      implantable cardiac defibrillators (ICD) has proven to be a valuable therapy in selected&#xD;
      patients with systolic heart failure, ameliorating both morbidity and mortality. However,&#xD;
      with current selection criteria and implant technique, about 20 to 30 % of patients remain&#xD;
      non-responders. Non-responders might be due to failing selection criteria or methodology in&#xD;
      casu echocardiography. Moreover, the definition of response to CRT is unequivocal and there&#xD;
      is a need for a simple and reproducible measure of response with low inter- and&#xD;
      intra-observer variability.&#xD;
&#xD;
      Primary objectives: This study evaluates the correlation between intrathoracic blood volume&#xD;
      (ITBV) measured by contrast enhanced ultrasound (CEUS) and magnetic resonance imaging (MRI),&#xD;
      as well as the feasibility to use intrathoracic blood volume as a predictor for response to&#xD;
      CRT.&#xD;
&#xD;
      Study design: a prospective nonrandomized pilot study Study population: patients with heart&#xD;
      failure New York Heart Association (NYHA) class III or IV, a left ventricular ejection&#xD;
      fraction equal to or less than 35% and a QRS-duration equal to or more than 0.12 seconds who&#xD;
      are referred to our centre for implantation of a CRT-P or CRT-D device.&#xD;
&#xD;
      Intervention: No specific intervention will be performed. Main study parameters: correlation&#xD;
      between intrathoracic bloodvolume measured by CEUS and MRI, correlation between LVEF measured&#xD;
      by CEUS and by standard 2D ultrasound (biplane methods of discs), change in intrathoracic&#xD;
      blood volume as a response to CRT.&#xD;
&#xD;
      Nature and extent of the burden and risks associated with participation, benefit and group&#xD;
      relatedness: at baseline a clinical examination, laboratory analysis, cardiopulmonary&#xD;
      exercise testing, echocardiography and cardiac magnetic resonance imaging will be performed.&#xD;
      All of these examinations will be repeated at 3-months follow-up except for the cardiac&#xD;
      magnetic resonance imaging. All examinations, except for the MRI, are part of the standard&#xD;
      workup in our hospital for patients undergoing implantation of a CRT device. Data needed for&#xD;
      the purpose of this study, will be acquired by offline image analysis with dedicated&#xD;
      software.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>a. change in ITBV measured by CEUS before and after CRT</measure>
    <time_frame>two years anticipated</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>b. correlation of ITBV measured by CEUS and MRI before CRT</measure>
    <time_frame>two years anticipated</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>a. correlation between LVEF estimated with CEUS and standard contrast 2D ultrasound</measure>
    <time_frame>two years anticipated</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>b. correlation between LVEF estimated with CEUS and MRI</measure>
    <time_frame>two years anticipated</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Intrathoracic Blood Volume in Heart Failure Patients</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients referred to our centre for implantation of a CRT-P or CRT-D device are&#xD;
        eligible. In the pilot phase 20 patients will be included. Data will be collected at&#xD;
        baseline and 3 months post-implantation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18y&#xD;
&#xD;
          2. LVEF ≤35%&#xD;
&#xD;
          3. QRS-duration ≥0.12 seconds&#xD;
&#xD;
          4. NYHA functional class III or IV despite optimal medical therapy defined as use of&#xD;
             angiotensin-converting enzyme inhibitors or angiotensin-II receptor blocker and&#xD;
             beta-blockers unless they are not tolerated or contra-indicated&#xD;
&#xD;
          5. sinus rhythm or atrial fibrillation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. episode of acute heart failure ≤3 months&#xD;
&#xD;
          2. change in dosage of beta-blockers, angiotensin-converting enzyme inhibitors or&#xD;
             angiotensin-II receptor blockers ≤3 months&#xD;
&#xD;
          3. unstable angina pectoris, acute myocardial infarction, percutaneous intervention or&#xD;
             coronary bypass surgery ≤3 months&#xD;
&#xD;
          4. chronic atrial arrhythmias other than atrial fibrillation&#xD;
&#xD;
          5. any mechanical or biological valve prosthesis&#xD;
&#xD;
          6. atrial septal defect&#xD;
&#xD;
          7. right-to-left shunt&#xD;
&#xD;
          8. severe pulmonary hypertension (systolic pulmonary artery pressure &gt;90 mmHg)&#xD;
&#xD;
          9. uncontrolled arterial hypertension&#xD;
&#xD;
         10. known allergy to sulphur hexafluoride&#xD;
&#xD;
         11. end-stage renal or hepatic disease&#xD;
&#xD;
         12. inability to provide written informed consent&#xD;
&#xD;
         13. pregnancy or childbearing potential without use of birth-control measurements&#xD;
&#xD;
         14. general contra-indications to magnetic resonance imaging&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>I.H.F. Herold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catharina Ziekenhuis Eindhoven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Catharina Hospital Eindhoven</name>
      <address>
        <city>Eindhoven</city>
        <zip>4194 TR</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>November 26, 2012</study_first_submitted>
  <study_first_submitted_qc>November 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2012</study_first_posted>
  <last_update_submitted>January 27, 2016</last_update_submitted>
  <last_update_submitted_qc>January 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catharina Ziekenhuis Eindhoven</investigator_affiliation>
    <investigator_full_name>Ingeborg Herold</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

